Fellow pharma powerhouse Roche has also jumped into the oral obesity arena with the $2.7 billion acquisition of Carmot Therapeutics in December 2023, giving it access to CT-388 and CT-868, both of which are dual agonists of the GLP-1 and GIP receptors with best-in-class potential for obesity, Roche said at the time
A few things stand out from this comparison beyond the top-line weight loss figures
The experiment involved several treatment groups across multiple animal models
For many patients who are not ready for pregnancy, long-acting reversible contraceptives such as IUDs or implants may be a more reliable option
The findings suggest a no-win situation in which individuals may face stigma whether they lose weight with medication, regain it, or remain at a higher weight
Subcutaneous administration suffers from: Lower bioavailability Variable absorption Different pharmacokinetics Which means the systemic exposure of DSIP via subcutaneous administration is not equivalent to what is achieved with intravenous infusion